Samum Verm\u00f6\u00adgens\u00adver\u00adwal\u00adtungs<\/strong> GmbH (Hamburg). Pacira Biosci\u00aden\u00adces, Inc. and Samum Verm\u00f6\u00adgens\u00adver\u00adwal\u00adtungs GmbH also provide conver\u00adti\u00adble loans in the amount of \u20ac2.75 million. A further \u20ac0.9 million comes in the form of subsi\u00addies from the Inves\u00adti\u00adti\u00adons\u00adbank des Landes Brandenburg.<\/p>\nGeneQuine will use the funds raised to deve\u00adlop lead candi\u00addate GQ-303 for the treat\u00adment of osteo\u00adar\u00adthri\u00adtis through to a Phase 1 clini\u00adcal trial. Further\u00admore, the deve\u00adlo\u00adp\u00adment of new gene therapy drugs for the treat\u00adment of inter\u00adver\u00adte\u00adbral disc dege\u00adne\u00adra\u00adtion will be advan\u00adced, and GeneQui\u00adne\u2019s gene therapy vector plat\u00adform will be further expan\u00added. GeneQuine alre\u00adady expan\u00added its work\u00adforce last year and estab\u00adlished a subsi\u00addiary in Li\u00e8ge (Belgium). GeneQuine has its head\u00adquar\u00adters in Hamburg and a rese\u00adarch and deve\u00adlo\u00adp\u00adment labo\u00adra\u00adtory in Lucken\u00adwalde (Grea\u00adter Berlin).<\/p>\n
GeneQuine uses a gene therapy vector plat\u00adform based on \u201cHelper-depen\u00addent Adeno\u00advi\u00adral Vectors\u201d (HDAd) to trans\u00adform tissues and organs affec\u00adted by dise\u00adase into \u201cfacto\u00adries\u201d for local produc\u00adtion of thera\u00adpeu\u00adtic prote\u00adins. A single, local injec\u00adtion of a gene therapy drug could thus lead to protein produc\u00adtion over seve\u00adral years without the need for repea\u00adted appli\u00adca\u00adtion requi\u00adred for most conven\u00adtio\u00adnal drugs.<\/p>\n
GQ-303 is an HDAd vector that produ\u00adces the protein proteo\u00adgly\u00adcan 4 and is curr\u00adently in precli\u00adni\u00adcal deve\u00adlo\u00adp\u00adment. Proteo\u00adgly\u00adcan 4 (also known as lubri\u00adcin) has been shown to have a dual mecha\u00adnism of action in the treat\u00adment of osteo\u00adar\u00adthri\u00adtis: On the one hand, it has a biome\u00adcha\u00adni\u00adcal effect due to lubri\u00adca\u00adting proper\u00adties, and on the other hand, it has effects on mole\u00adcu\u00adlar mecha\u00adnisms that lead to the inhi\u00adbi\u00adtion of pain, inflamm\u00ada\u00adtion and carti\u00adlage dege\u00adne\u00adra\u00adtion. Ther\u00ade\u00adfore, GQ-303 has the poten\u00adtial to have both sympto\u00adma\u00adtic and dise\u00adase-modi\u00adfy\u00ading effi\u00adcacy in the treat\u00adment of osteo\u00adar\u00adthri\u00adtis, which has alre\u00adady been demons\u00adtra\u00adted in seve\u00adral precli\u00adni\u00adcal in vivo models.<\/p>\n
GeneQuine is in advan\u00adced nego\u00adtia\u00adti\u00adons with a suita\u00adble contract manu\u00adfac\u00adtu\u00adrer for the produc\u00adtion of GQ-303 for toxi\u00adco\u00adlogy and clini\u00adcal studies. Follo\u00adwing produc\u00adtion and formal toxi\u00adco\u00adlogy studies with GQ-303, appr\u00adoval for a Phase 1 clini\u00adcal trial will be sought. GeneQui\u00adne\u2019s former lead candi\u00addate, an HDAd vector that produ\u00adces the protein interleukin\u20111 (now refer\u00adred to as FX201), was sold in 2017 to the phar\u00admaceu\u00adti\u00adcal company Flexion Thera\u00adpeu\u00adtics, Inc. (Burling\u00adton, USA).<\/p>\n
Flexion has since initia\u00adted a Phase 1 clini\u00adcal trial and trea\u00adted multi\u00adple pati\u00adents in two dose groups with FX201. Because both GQ-303 and FX201 are HDAd vectors and both are injec\u00adted intra-arti\u00adcu\u00adlarly (directly into the joint), GeneQuine esti\u00adma\u00adtes that most vector-rela\u00adted deve\u00adlo\u00adp\u00adment risks for GQ-303 are mini\u00admi\u00adzed. Although GQ-303 and FX201 are both being deve\u00adlo\u00adped for knee osteo\u00adar\u00adthri\u00adtis, GeneQuine will focus on a speci\u00adfic pati\u00adent popu\u00adla\u00adtion with GQ-303 that can poten\u00adti\u00adally bene\u00adfit most from the dual mecha\u00adnism of action of proteo\u00adgly\u00adcan 4.<\/p>\n
GeneQuine is also deve\u00adlo\u00adping HDAd vector-based gene therapy drugs for the treat\u00adment of disc dege\u00adne\u00adra\u00adtion. Despite the very high unmet medi\u00adcal need in the treat\u00adment of disc dege\u00adne\u00adra\u00adtion \u2014 one of the main causes of chro\u00adnic low back pain \u2014 no dise\u00adase-modi\u00adfy\u00ading drugs are available for this indi\u00adca\u00adtion. GeneQui\u00adne\u2019s data show that gene therapy with HDAd vectors has great poten\u00adtial in the deve\u00adlo\u00adp\u00adment of sympto\u00adma\u00adtic and dise\u00adase-modi\u00adfy\u00ading drugs for this disease.<\/p>\n
\u201cWe are very plea\u00adsed to have closed this finan\u00adcing round and will now use the capi\u00adtal effi\u00adci\u00adently to bring GQ-303 into the clinic, expand our gene therapy program for the treat\u00adment of disc dege\u00adne\u00adra\u00adtion, and expand our HDAd vector plat\u00adform. We would like to thank all inves\u00adtors in this finan\u00adcing round for their trust and support. In parti\u00adcu\u00adlar, we are plea\u00adsed to have Pacira as an inves\u00adtor with their strong exper\u00adtise in clini\u00adcal drug deve\u00adlo\u00adp\u00adment in the muscu\u00adlos\u00adke\u00adle\u00adtal field,\u201d Kilian Guse, CEO of GeneQuine (photo)<\/strong>.<\/p>\n\u201cOur equity invest\u00adment in GeneQuine repres\u00adents a signi\u00adfi\u00adcant oppor\u00adtu\u00adnity to parti\u00adci\u00adpate in the deve\u00adlo\u00adp\u00adment of what we believe is an exci\u00adting dise\u00adase-modi\u00adfy\u00ading gene therapy for osteo\u00adar\u00adthri\u00adtis. GeneQuine is conduc\u00adting precli\u00adni\u00adcal work to support the initia\u00adtion of human studies in appro\u00adxi\u00adm\u00adately two years. In addi\u00adtion to our confi\u00addence in this tran\u00adsac\u00adtion as a sound invest\u00adment, we enthu\u00adsi\u00ada\u00adsti\u00adcally look forward to the matu\u00adra\u00adtion of data and for further oppor\u00adtu\u00adnity to parti\u00adci\u00adpate in GeneQui\u00adne\u2019s successful precli\u00adni\u00adcal program and entry into the clinic. Importantly, this invest\u00adment is consis\u00adtent with our mission to advance inno\u00adva\u00adtive pain manage\u00adment and rege\u00adne\u00adra\u00adtive health solu\u00adti\u00adons,\u201d Ron Ellis, Senior Vice Presi\u00addent, Corpo\u00adrate Stra\u00adtegy and Busi\u00adness Deve\u00adlo\u00adp\u00adment at Pacira.<\/p>\n
\u201cGeneQuine is a great exam\u00adple of a typi\u00adcal HTGF invest\u00adment: a new gene\u00adti\u00adcally engi\u00adnee\u00adred drug disco\u00advery plat\u00adform that broke comple\u00adtely new scien\u00adti\u00adfic ground when we made our seed invest\u00adment in 2012. That combi\u00adned with a strong team capa\u00adble of advan\u00adcing gene therapy agents toward the clinic as effi\u00adci\u00adently as possi\u00adble. We look forward to support\u00ading GeneQuine toge\u00adther with the inter\u00adna\u00adtio\u00adnal inves\u00adtor consor\u00adtium and Paci\u00adra\u2019s exper\u00adtise in deve\u00adlo\u00adping their promi\u00adsing pipe\u00adline,\u201d Martin Pfis\u00adter, Prin\u00adci\u00adpal at High-Tech Gr\u00fcnderfonds<\/p>\n
About GeneQuine Biothe\u00adra\u00adpeu\u00adtics GmbH
\n<\/strong>
\nGeneQuine Biothe\u00adra\u00adpeu\u00adtics GmbH is a biotech company deve\u00adlo\u00adping inno\u00adva\u00adtive gene therapy drugs for the treat\u00adment of muscu\u00adlos\u00adke\u00adle\u00adtal dise\u00ada\u00adses. GeneQuine uses a gene therapy plat\u00adform to turn tissues and organs affec\u00adted by dise\u00adase into \u201cfacto\u00adries\u201d for local produc\u00adtion of thera\u00adpeu\u00adtic prote\u00adins. Lead candi\u00addate GQ-303 is being deve\u00adlo\u00adped as a topi\u00adcally applied drug for the treat\u00adment of osteo\u00adar\u00adthri\u00adtis and has shown great poten\u00adtial to have sympto\u00adma\u00adtic and dise\u00adase-modi\u00adfy\u00ading effi\u00adcacy in multi\u00adple animal models. GeneQui\u00adne\u2019s former lead candi\u00addate for the treat\u00adment of osteo\u00adar\u00adthri\u00adtis, which is based on the same gene therapy vector tech\u00adno\u00adlogy as GQ-303, was sold in 2017 to phar\u00admaceu\u00adti\u00adcal company Flexion Thera\u00adpeu\u00adtics, Inc. (Burling\u00adton, USA) and is curr\u00adently being tested in a Phase 1 clini\u00adcal trial. GeneQuine has a head office in Hamburg and branch offices in Lucken\u00adwalde (Grea\u00adter Berlin) and Li\u00e8ge (Belgium). www.genequine.com<\/p>\nAbout High-Tech Gr\u00fcnderfonds
\n<\/strong>
\nThe seed inves\u00adtor High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF) finan\u00adces tech\u00adno\u00adlogy start-ups with growth poten\u00adtial. With a volume of around EUR 900 million spread across three funds and an inter\u00adna\u00adtio\u00adnal part\u00adner network, HTGF has supported almost 600 start-ups since 2005. His team of expe\u00adri\u00aden\u00adced invest\u00adment mana\u00adgers and start-up experts supports the young compa\u00adnies with know-how, entre\u00adpre\u00adneu\u00adrial spirit and passion. The focus is on high-tech start-ups in the fields of digi\u00adtal tech, indus\u00adtrial tech, life scien\u00adces, chemis\u00adtry and rela\u00adted busi\u00adness areas. Over \u20ac2.8 billion in capi\u00adtal has been inves\u00adted in the HTGF port\u00adfo\u00adlio by exter\u00adnal inves\u00adtors in more than 1,600 follow-on finan\u00adcing rounds to date. In addi\u00adtion, the fund has alre\u00adady successfully sold shares in more than 100 companies.<\/p>\n","protected":false},"excerpt":{"rendered":"Hamburg\/ Bonn \u2014 GeneQuine Biothe\u00adra\u00adpeu\u00adtics GmbH, a biotech company deve\u00adlo\u00adping gene therapy drugs for the treat\u00adment of muscu\u00adlos\u00adke\u00adle\u00adtal dise\u00ada\u00adses, announ\u00adces the closing of a \u20ac5.4 million Series A finan\u00adcing round and the raising of \u20ac3.65 million in conver\u00adti\u00adble loans and grants. The Series A finan\u00adcing round is led by Pacira BioSci\u00aden\u00adces, Inc (Parsippany, USA), a [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":36585,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1369,1373],"tags":[],"class_list":["post-43366","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-investors","category-venture-capital-en","news-category-venture-capital-news"],"yoast_head":"\n
GeneQuine Biotherapeutics Receives \u20ac9 Million Series A Financing - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GeneQuine Biotherapeutics Receives \u20ac9 Million Series A Financing - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Hamburg\/ Bonn \u2014 GeneQuine Biothe\u00adra\u00adpeu\u00adtics GmbH, a biotech company deve\u00adlo\u00adping gene therapy drugs for the treat\u00adment of muscu\u00adlos\u00adke\u00adle\u00adtal dise\u00ada\u00adses, announ\u00adces the closing of a \u20ac5.4 million Series A finan\u00adcing round and the raising of \u20ac3.65 million in conver\u00adti\u00adble loans and grants. The Series A finan\u00adcing round is led by Pacira BioSci\u00aden\u00adces, Inc (Parsippany, USA), a […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-27T09:43:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/01\/a-kilian_guse.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"560\" \/>\n\t<meta property=\"og:image:height\" content=\"560\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"GeneQuine Biotherapeutics Receives \u20ac9 Million Series A Financing\",\"datePublished\":\"2021-01-27T09:43:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/\"},\"wordCount\":1111,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/01\/a-kilian_guse.jpg\",\"articleSection\":[\"General\",\"Featured\",\"News\",\"Investors\",\"Venture Capital\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/\",\"url\":\"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/\",\"name\":\"GeneQuine Biotherapeutics Receives \u20ac9 Million Series A Financing - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/01\/a-kilian_guse.jpg\",\"datePublished\":\"2021-01-27T09:43:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/01\/a-kilian_guse.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/01\/a-kilian_guse.jpg\",\"width\":560,\"height\":560,\"caption\":\"Dr. Kilian Guse, CEO, Co-Founder of GeneQuine Biotherapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GeneQuine Biotherapeutics Receives \u20ac9 Million Series A Financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GeneQuine Biotherapeutics Receives \u20ac9 Million Series A Financing - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/","og_locale":"en_US","og_type":"article","og_title":"GeneQuine Biotherapeutics Receives \u20ac9 Million Series A Financing - FYB Financial Yearbook","og_description":"Hamburg\/ Bonn \u2014 GeneQuine Biothe\u00adra\u00adpeu\u00adtics GmbH, a biotech company deve\u00adlo\u00adping gene therapy drugs for the treat\u00adment of muscu\u00adlos\u00adke\u00adle\u00adtal dise\u00ada\u00adses, announ\u00adces the closing of a \u20ac5.4 million Series A finan\u00adcing round and the raising of \u20ac3.65 million in conver\u00adti\u00adble loans and grants. The Series A finan\u00adcing round is led by Pacira BioSci\u00aden\u00adces, Inc (Parsippany, USA), a […]","og_url":"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2021-01-27T09:43:04+00:00","og_image":[{"width":560,"height":560,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/01\/a-kilian_guse.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"GeneQuine Biotherapeutics Receives \u20ac9 Million Series A Financing","datePublished":"2021-01-27T09:43:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/"},"wordCount":1111,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/01\/a-kilian_guse.jpg","articleSection":["General","Featured","News","Investors","Venture Capital"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/","url":"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/","name":"GeneQuine Biotherapeutics Receives \u20ac9 Million Series A Financing - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/01\/a-kilian_guse.jpg","datePublished":"2021-01-27T09:43:04+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/01\/a-kilian_guse.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/01\/a-kilian_guse.jpg","width":560,"height":560,"caption":"Dr. Kilian Guse, CEO, Co-Founder of GeneQuine Biotherapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/genequine-biotherapeutics-receives-e9-million-series-a-financing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"GeneQuine Biotherapeutics Receives \u20ac9 Million Series A Financing"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=43366"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43366\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/36585"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=43366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=43366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=43366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}